BBR Partners LLC Takes Position in Enzo Biochem, Inc. (NYSE:ENZ)

BBR Partners LLC bought a new position in Enzo Biochem, Inc. (NYSE:ENZ) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 100,000 shares of the medical research company’s stock, valued at approximately $112,000.

Separately, XTX Topco Ltd lifted its holdings in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares during the period. 36.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Enzo Biochem in a research note on Saturday, November 23rd. They set a “hold” rating for the company.

Enzo Biochem Stock Performance

Enzo Biochem stock opened at $1.03 on Friday. The business has a 50 day simple moving average of $1.11 and a 200 day simple moving average of $1.11. Enzo Biochem, Inc. has a one year low of $0.93 and a one year high of $1.50.

Enzo Biochem Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be issued a $0.10 dividend. This represents a $0.40 annualized dividend and a dividend yield of 38.83%. The ex-dividend date of this dividend is Friday, November 15th.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.